Sergey L. Gutorov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sergey L. Gutorov has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Alexey A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - Tatiana E. Tikhomirova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
4 shared publications - A. Yu. Anokhin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - A. N. Lud
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - E. I. Borisova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Sergei A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 35-43
Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population
Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 35-43
Open AccessFrontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population
Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 67-74
Systemic drug therapy for metastatic uterine leiomyosarcoma: treatment results from real clinical practice
Background. Currently, adjuvant chemotherapy of choice after surgical treatment of uterine leiomyosarcoma is doxorubicin. The same approach is used for the 1st line of systemic drug therapy in patients with initially metastatic process, or those who have not previously received adjuvant treatment with anthracyclines. Disseminated forms of metastatic leiomyosarcoma are characterized by unfavorable prognosis, and the options for potentially effective drug treatments are limited. Aim. To evaluate the efficacy of 1st and 2nd line chemotherapy regimens for uterine leiomyosarcoma in a population of patients in real clinical practice. Materials and methods. The retrospective analysis included 43 patients with histologically verified uterine leiomyosarcoma. The study included patients with primarily localized forms of the disease, who underwent surgical treatment at the 1st stage (with or without adjuvant chemotherapy), and patients with initially metastatic disease. All patients had a history of 1–2 lines of systemic drug therapy due to disease progression. Results. The analysis included 43 patients who underwent treatment at the N. N. Blokhin National Medical Research Center of Oncology between 2021 and 2024. The efficacy of the 1st line was assessed in 35 (81.4 %) patients: the objective response rate reached 17.6 %, and median progression-free survival from the start of the 1st line was 7.4 months. The efficacy of 2nd line of therapy was assessed in 18 (41.9 %) patients: the objective response rate was 11.1 %, median progression-free survival from the start of the 1st line to progression after the 2nd line was 13.2 months, and median progression-free survival from the start of the 2nd line to progression after it was 3.3 months. Conclusion. Analysis of the efficacy of systemic drug therapy for uterine leiomyosarcoma in real clinical practice demonstrates comparable long-term treatment results with data from international literature. Further study of the efficacy of combined adjuvant and 1st line therapy regimens seems promising.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 67-74
Systemic drug therapy for metastatic uterine leiomyosarcoma: treatment results from real clinical practice
Background. Currently, adjuvant chemotherapy of choice after surgical treatment of uterine leiomyosarcoma is doxorubicin. The same approach is used for the 1st line of systemic drug therapy in patients with initially metastatic process, or those who have not previously received adjuvant treatment with anthracyclines. Disseminated forms of metastatic leiomyosarcoma are characterized by unfavorable prognosis, and the options for potentially effective drug treatments are limited. Aim. To evaluate the efficacy of 1st and 2nd line chemotherapy regimens for uterine leiomyosarcoma in a population of patients in real clinical practice. Materials and methods. The retrospective analysis included 43 patients with histologically verified uterine leiomyosarcoma. The study included patients with primarily localized forms of the disease, who underwent surgical treatment at the 1st stage (with or without adjuvant chemotherapy), and patients with initially metastatic disease. All patients had a history of 1–2 lines of systemic drug therapy due to disease progression. Results. The analysis included 43 patients who underwent treatment at the N. N. Blokhin National Medical Research Center of Oncology between 2021 and 2024. The efficacy of the 1st line was assessed in 35 (81.4 %) patients: the objective response rate reached 17.6 %, and median progression-free survival from the start of the 1st line was 7.4 months. The efficacy of 2nd line of therapy was assessed in 18 (41.9 %) patients: the objective response rate was 11.1 %, median progression-free survival from the start of the 1st line to progression after the 2nd line was 13.2 months, and median progression-free survival from the start of the 2nd line to progression after it was 3.3 months. Conclusion. Analysis of the efficacy of systemic drug therapy for uterine leiomyosarcoma in real clinical practice demonstrates comparable long-term treatment results with data from international literature. Further study of the efficacy of combined adjuvant and 1st line therapy regimens seems promising.
- 4 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 8
Olanzapine in the prevention and treatment of cancer-related anorexia-cachexia syndrome: interim results
Introduction. Anorexia-cachexia syndrome (ACS) and associated weight loss are common complications in cancer patients, reducing quality of life and survival. Efforts to prevent the development and correct ACS are relevant for improving treatment outcomes in preoperative chemotherapy for several malignancies. Preventing weight loss may reduce the frequency and severity of complications from chemotherapy and surgical treatment, maintain adequate dose intensity of chemotherapy, and improve patients’ quality of life. Olanzapine, an atypical antipsychotic, has demonstrated potential not only in controlling nausea but also in improving appetite in patients receiving chemotherapy. Objective. To evaluate the efficacy and safety of prolonged low-dose olanzapine (2.5 mg/day) in preventing significant weight loss (≥5 %) in patients with localized/locally advanced gastric cancer and disseminated ovarian cancer during preoperative chemotherapy. Materials and methods. The analysis included 30 patients. Of these, 14 were diagnosed with disseminated ovarian cancer and 16 with locally advanced gastric cancer. These tumor types were selected because the treatment plan includes a preoperative chemotherapy block followed by surgery. Preoperative treatment consisted of 3–4 cycles of systemic chemotherapy according to the nosology. A summary of patient characteristics and chemotherapy regimens is presented in Table 1. The experimental group received low-dose olanzapine (2.5 mg orally at night) daily until surgical treatment while maintaining their dietary habits. In the control group, no additional medications were prescribed, and patients adhered to their dietary habits. In both groups, nutritional support and the use of olanzapine as a component of antiemetic therapy were permitted when indicated. In the experimental group, dose escalation to the standard dose (5 mg) on days 1–4 of each chemotherapy cycle was allowed for this purpose. In the control group, olanzapine was administered at a dose of 5 mg orally on days 1–4 of each cycle as antiemetic therapy. Anthropometric parameters (height, weight, body mass index, body surface area) were assessed before the start of chemotherapy and after 3–4 cycles. Adverse events of chemotherapy were evaluated before each cycle, and surgical complications were assessed within 30 days after surgery. The primary endpoint of the study was the proportion of patients with weight loss ≤5 %. Due to the small sample size, descriptive analysis was used. Results. Among patients who experienced weight loss during preoperative chemotherapy (n=16/30), weight loss of less than 5 % was more frequently observed in the olanzapine group – in 85 % (6 out of 7) – compared to 33 % (3 out of 9) in the control group (p>0.05). Weight stability was associated with a lower incidence of postoperative complications in the olanzapine group (13 % vs. 46.7 %) and prevented a reduction in relative dose intensity to Conclusion. Preliminary data suggest a potential benefit of prolonged olanzapine administration at 2.5 mg/day in preventing significant nutritional deficiency and improving treatment tolerability.
- 4 June 2026
- Published by Alfmed LLC in Medical alphabet
- No. 8
Olanzapine in the prevention and treatment of cancer-related anorexia-cachexia syndrome: interim results
Introduction. Anorexia-cachexia syndrome (ACS) and associated weight loss are common complications in cancer patients, reducing quality of life and survival. Efforts to prevent the development and correct ACS are relevant for improving treatment outcomes in preoperative chemotherapy for several malignancies. Preventing weight loss may reduce the frequency and severity of complications from chemotherapy and surgical treatment, maintain adequate dose intensity of chemotherapy, and improve patients’ quality of life. Olanzapine, an atypical antipsychotic, has demonstrated potential not only in controlling nausea but also in improving appetite in patients receiving chemotherapy. Objective. To evaluate the efficacy and safety of prolonged low-dose olanzapine (2.5 mg/day) in preventing significant weight loss (≥5 %) in patients with localized/locally advanced gastric cancer and disseminated ovarian cancer during preoperative chemotherapy. Materials and methods. The analysis included 30 patients. Of these, 14 were diagnosed with disseminated ovarian cancer and 16 with locally advanced gastric cancer. These tumor types were selected because the treatment plan includes a preoperative chemotherapy block followed by surgery. Preoperative treatment consisted of 3–4 cycles of systemic chemotherapy according to the nosology. A summary of patient characteristics and chemotherapy regimens is presented in Table 1. The experimental group received low-dose olanzapine (2.5 mg orally at night) daily until surgical treatment while maintaining their dietary habits. In the control group, no additional medications were prescribed, and patients adhered to their dietary habits. In both groups, nutritional support and the use of olanzapine as a component of antiemetic therapy were permitted when indicated. In the experimental group, dose escalation to the standard dose (5 mg) on days 1–4 of each chemotherapy cycle was allowed for this purpose. In the control group, olanzapine was administered at a dose of 5 mg orally on days 1–4 of each cycle as antiemetic therapy. Anthropometric parameters (height, weight, body mass index, body surface area) were assessed before the start of chemotherapy and after 3–4 cycles. Adverse events of chemotherapy were evaluated before each cycle, and surgical complications were assessed within 30 days after surgery. The primary endpoint of the study was the proportion of patients with weight loss ≤5 %. Due to the small sample size, descriptive analysis was used. Results. Among patients who experienced weight loss during preoperative chemotherapy (n=16/30), weight loss of less than 5 % was more frequently observed in the olanzapine group – in 85 % (6 out of 7) – compared to 33 % (3 out of 9) in the control group (p>0.05). Weight stability was associated with a lower incidence of postoperative complications in the olanzapine group (13 % vs. 46.7 %) and prevented a reduction in relative dose intensity to Conclusion. Preliminary data suggest a potential benefit of prolonged olanzapine administration at 2.5 mg/day in preventing significant nutritional deficiency and improving treatment tolerability.
- Open Access
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 88-96
dd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study
Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 88-96
Open Accessdd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study
Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.
- Open Access
- 17 December 2025
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 24 (4) , 39-46
Prognostic value of interleukins 6 and 8 in assessing the effectiveness of therapy in patients with triple-negative breast cancer
Background. Interleukin (IL) 6 is a potent proinflammatory pleiotropic cytokine and is a key factor in the immune escape of malignant cells. IL-8 (or CXCL8) is a proinflammatory chemokine, high levels of expression of which were observed in various types of cancer. Aim. To determine the relationship between the level of IL-6 and IL-8 cytokines in the blood serum with the main populations of peripheral blood lymphocytes and its significance for the results of neoadjuvant chemotherapy for triple-negative breast cancer (TN BC). Materials and methods. All 64 patients received chemotherapy and surgery. The concentrations of IL-6 and IL-8 (ng/ml) in the blood serum and the percentage of the main lymphocyte populations in the peripheral blood (PB) were determined. Results. The relationship between progression, metastasis and death of patients with higher IL-6 concentrations in the blood serum of patients with TN BC was demonstrated. Before treatment, a positive correlation was found between the IL-6 level and the percentage of HLA-DR, CD3+HLA-DR+, CD3–HLA-DR+ lymphocytes, which, as previously shown, are negative prognostic factors in TN BC. An increase in the IL-6 level was combined with a decrease in the percentage of CD4+ T lymphocytes. Conclusion. The obtained results are consistent with the position that IL-6 is a negative prognostic factor in patients with BC. The positive relationship between IL-6 and “negative” HLA-DR, CD3+HLA-DR+, CD3‒HLA-DR+ lymphocyte populations found in the work indicates their interaction in stimulating tumor growth.
- 17 December 2025
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 24 (4) , 39-46
Open AccessPrognostic value of interleukins 6 and 8 in assessing the effectiveness of therapy in patients with triple-negative breast cancer
Background. Interleukin (IL) 6 is a potent proinflammatory pleiotropic cytokine and is a key factor in the immune escape of malignant cells. IL-8 (or CXCL8) is a proinflammatory chemokine, high levels of expression of which were observed in various types of cancer. Aim. To determine the relationship between the level of IL-6 and IL-8 cytokines in the blood serum with the main populations of peripheral blood lymphocytes and its significance for the results of neoadjuvant chemotherapy for triple-negative breast cancer (TN BC). Materials and methods. All 64 patients received chemotherapy and surgery. The concentrations of IL-6 and IL-8 (ng/ml) in the blood serum and the percentage of the main lymphocyte populations in the peripheral blood (PB) were determined. Results. The relationship between progression, metastasis and death of patients with higher IL-6 concentrations in the blood serum of patients with TN BC was demonstrated. Before treatment, a positive correlation was found between the IL-6 level and the percentage of HLA-DR, CD3+HLA-DR+, CD3–HLA-DR+ lymphocytes, which, as previously shown, are negative prognostic factors in TN BC. An increase in the IL-6 level was combined with a decrease in the percentage of CD4+ T lymphocytes. Conclusion. The obtained results are consistent with the position that IL-6 is a negative prognostic factor in patients with BC. The positive relationship between IL-6 and “negative” HLA-DR, CD3+HLA-DR+, CD3‒HLA-DR+ lymphocyte populations found in the work indicates their interaction in stimulating tumor growth.
- Open Access
- 23 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 50-57
Impact of PARP inhibitor maintenance therapy after initial treatment on the efficacy of subsequent therapy in ovarian cancer: a propensity score matching analysis
Introduction: progression of advanced epithelial ovarian cancer (EOC) on olaparib may diminish the efficacy of subsequent chemotherapy in recurrent disease setting. However, the impact of progression of EOC during maintenance therapy with olaparib after frontline therapy has not been well studied.Materials and methods: this retrospective study enrolled patients of BRCA / HRD + FIGO stage III–IV EOC with confirmed progressive disease after frontline treatment treated since 2014 until 2022 who either received (arm A) or not (arm B) olaparib as maintenance therapy. To ensure the balance of the compared groups during the study propensity score matching analysis was conducted (cardinality method using MatchIT package in R) with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, the duration of platinum-free interval after the frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was progression-free survival (PFS).Results: the initial population consisted of 259 patients, after the matching procedure 76 patients were enrolled in the study. The median age of patients was 48 years in the arm A and 50 years in the arm B (p = 0.989), 12 (32 %) had FIGO stage IV in both arms (p = 1.000), 25 (66 %) patients in both arms had platinum-free interval ≥ 12 months. With a median follow-up of 42.8 mo. (0.6–70.1 months) median PFS was 6.9 (95 % CI 6.2–10.6 months) and 12.2 (95 % CI 9. 6–21.3 months) in arm A and B, respectively (hazard ratio [HR] 2.89; 95 % CI 1.63–5.12; p < 0.001). Median overall survival was 23.2 months. and 68.2 mo., respectively (HR 4.15; 95 % CI 1.62–10.6).Conclusion: efficacy of subsequent chemotherapy is apparently reduced following progression of BRCA / HRD + EOC on maintenance olaparib therapy in frontline setting. Further trials should assess optimal approaches for these patients.
- 23 January 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (4) , 50-57
Open AccessImpact of PARP inhibitor maintenance therapy after initial treatment on the efficacy of subsequent therapy in ovarian cancer: a propensity score matching analysis
Introduction: progression of advanced epithelial ovarian cancer (EOC) on olaparib may diminish the efficacy of subsequent chemotherapy in recurrent disease setting. However, the impact of progression of EOC during maintenance therapy with olaparib after frontline therapy has not been well studied.Materials and methods: this retrospective study enrolled patients of BRCA / HRD + FIGO stage III–IV EOC with confirmed progressive disease after frontline treatment treated since 2014 until 2022 who either received (arm A) or not (arm B) olaparib as maintenance therapy. To ensure the balance of the compared groups during the study propensity score matching analysis was conducted (cardinality method using MatchIT package in R) with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, the duration of platinum-free interval after the frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was progression-free survival (PFS).Results: the initial population consisted of 259 patients, after the matching procedure 76 patients were enrolled in the study. The median age of patients was 48 years in the arm A and 50 years in the arm B (p = 0.989), 12 (32 %) had FIGO stage IV in both arms (p = 1.000), 25 (66 %) patients in both arms had platinum-free interval ≥ 12 months. With a median follow-up of 42.8 mo. (0.6–70.1 months) median PFS was 6.9 (95 % CI 6.2–10.6 months) and 12.2 (95 % CI 9. 6–21.3 months) in arm A and B, respectively (hazard ratio [HR] 2.89; 95 % CI 1.63–5.12; p < 0.001). Median overall survival was 23.2 months. and 68.2 mo., respectively (HR 4.15; 95 % CI 1.62–10.6).Conclusion: efficacy of subsequent chemotherapy is apparently reduced following progression of BRCA / HRD + EOC on maintenance olaparib therapy in frontline setting. Further trials should assess optimal approaches for these patients.
- 6 December 2021
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (31) , 20-24
Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report)
In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic due to the limited amount of effective and low-toxic cytostatics. In our opinion, in this situation the use of eribulin which possesses unique antitumor action mechanisms is a good option. An illustrative case of a pronounced antitumor effect of eribulin in metastatic breast cancer with triple negative phenotype resistant to previous lines of chemotherapy is presented.
- 6 December 2021
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (31) , 20-24
Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report)
In most cases triple negative breast cancer is characterized by an aggressive course of disease and early development of resistance to chemotherapy. Thereafter, the late-line treatment choice, usually after anthracyclines and taxanes, is problematic due to the limited amount of effective and low-toxic cytostatics. In our opinion, in this situation the use of eribulin which possesses unique antitumor action mechanisms is a good option. An illustrative case of a pronounced antitumor effect of eribulin in metastatic breast cancer with triple negative phenotype resistant to previous lines of chemotherapy is presented.
- Open Access
- 7 August 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 42-47
Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation
Tyrosine kinase inhibitors of the first, second and third generations are the main treatment method for non-small cell lung cancer with EGFR mutation. About 60% of patients progressing on a first-generation or second-generation tyrosine kinase inhibitor acquire T790M mutation. An alternative is first-line osimertinib, but second-line treatment options are limited, and therefore it is important to find a strategy that allows to extend the effective treatment of TKI. One of the rational approaches is the use of a combination of a first-generation tyrosine kinase inhibitor with anti-VEGF agents. The available information sources show an increase in the effectiveness of the combined use of erlotinib and antiangiogenic drugs-bevacizumab and ramucirumab. The combination of erlotinib and bevacizumab in several studies of the second — third phase, led to a statistically significant increase in progression-free survival, but did not show a significant increase in overall survival. In the Phase 3 RELAY study, the combination of erlotinib and ramucirumab showed comparable efficacy with the third-generation TKI — osimertinib in the first line, however, overall survival results are not yet available. At the same time, there are more opportunities to choose the secondline mode, taking into account the known frequency of detection of the T790M mutation. The optimal treatment sequence is discussed, with the option of prescribing a combination of erlotinib with bevacizumab or ramucirumab in the first line and osimertinib in the second in the presence of the T790M mutation. In such patients, osimertinib may be prescribed in the second line.
- 7 August 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 42-47
Open AccessErlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation
Tyrosine kinase inhibitors of the first, second and third generations are the main treatment method for non-small cell lung cancer with EGFR mutation. About 60% of patients progressing on a first-generation or second-generation tyrosine kinase inhibitor acquire T790M mutation. An alternative is first-line osimertinib, but second-line treatment options are limited, and therefore it is important to find a strategy that allows to extend the effective treatment of TKI. One of the rational approaches is the use of a combination of a first-generation tyrosine kinase inhibitor with anti-VEGF agents. The available information sources show an increase in the effectiveness of the combined use of erlotinib and antiangiogenic drugs-bevacizumab and ramucirumab. The combination of erlotinib and bevacizumab in several studies of the second — third phase, led to a statistically significant increase in progression-free survival, but did not show a significant increase in overall survival. In the Phase 3 RELAY study, the combination of erlotinib and ramucirumab showed comparable efficacy with the third-generation TKI — osimertinib in the first line, however, overall survival results are not yet available. At the same time, there are more opportunities to choose the secondline mode, taking into account the known frequency of detection of the T790M mutation. The optimal treatment sequence is discussed, with the option of prescribing a combination of erlotinib with bevacizumab or ramucirumab in the first line and osimertinib in the second in the presence of the T790M mutation. In such patients, osimertinib may be prescribed in the second line.